Jump to content

Bupropion: Difference between revisions

From Pharmacopedia
[checked revision][checked revision]
Pharmacopedia: remove contraindications parameter
Pharmacopedia: add <pharmaInteractions/>
Line 22: Line 22:
| dosing            =  
| dosing            =  
| effects            =  
| effects            =  
| interactions      =  
| interactions      = <pharmaInteractions/>
| pregnancy_details  =  
| pregnancy_details  =  
| monitoring        =  
| monitoring        =  

Revision as of 03:30, 14 May 2026

NDRI, Antidepressant, Stimulant
Bupropion
Wellbutrin

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions5 edges
Pharmacokinetic mechanismSubstrate / metabolism relationships from primary literature
Enzyme:CYP2D6 inhibitor strong Primary 85 / 100
Strong CYP2D6 inhibitor at therapeutic doses; reduces morphine generation from codeine.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred from pharmacokinetic dataMaterialised by the inference engine; provenance shown per row
Codeine pk lowers via CYP2D6 Inferred 85 / 100
Bupropion inhibits CYP2D6 (inhibitor_strong, intensity 85); Codeine is a prodrug_activated_by of CYP2D6 (intensity 100). Derived: Codeine exposure lowered.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred via Enzyme:CYP2D6 (exposure lowered)
Desipramine pk raises via CYP2D6 Inferred 68 / 100
Bupropion inhibits CYP2D6 (inhibitor_strong, intensity 85); Desipramine is a substrate_major of CYP2D6 (intensity 80). Derived: Desipramine exposure raised.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred via Enzyme:CYP2D6 (exposure raised)
Dextromethorphan pk raises via CYP2D6 Inferred 68 / 100
Bupropion inhibits CYP2D6 (inhibitor_strong, intensity 85); Dextromethorphan is a substrate_major of CYP2D6 (intensity 80). Derived: Dextromethorphan exposure raised.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred via Enzyme:CYP2D6 (exposure raised)
Nebivolol pk raises via CYP2D6 Inferred 68 / 100
Bupropion inhibits CYP2D6 (inhibitor_strong, intensity 85); Nebivolol is a substrate_major of CYP2D6 (intensity 80). Derived: Nebivolol exposure raised.
reversible competitive, effect resolves over ~5 inhibitor half-lives
Inferred via Enzyme:CYP2D6 (exposure raised)

Patient experience

Fluoxetine via Category:Antidepressants👤 exp n/a/5 outcome n/a (n=1)⚕️ exp 1.0/5 outcome +33.0 (n=1)

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Pharmacy
Common uses
Classification(s)
Classes
NDRI, Antidepressant, Stimulant
Pharmacology
Purported mechanism
Norepinephrine–dopamine reuptake inhibitor
Pharmacopedia is intended for reference. Nothing here is advice. In an emergency call 911; US Poison Control 1-800-222-1222. See the full disclaimer.